Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 17 | 2025 | 305 | 3.610 |
Why?
|
| Ovarian Neoplasms | 10 | 2025 | 610 | 1.850 |
Why?
|
| Cystadenocarcinoma, Serous | 5 | 2025 | 33 | 1.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 435 | 1.440 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2025 | 349 | 1.240 |
Why?
|
| Uterine Neoplasms | 4 | 2025 | 80 | 1.110 |
Why?
|
| Hysterectomy | 10 | 2025 | 86 | 1.100 |
Why?
|
| Chemoradiotherapy | 6 | 2025 | 50 | 1.060 |
Why?
|
| Genital Neoplasms, Female | 2 | 2018 | 67 | 0.860 |
Why?
|
| Neoplasm Staging | 14 | 2025 | 481 | 0.860 |
Why?
|
| Endometrial Neoplasms | 6 | 2024 | 189 | 0.850 |
Why?
|
| Female | 41 | 2025 | 15826 | 0.830 |
Why?
|
| Cisplatin | 4 | 2025 | 186 | 0.820 |
Why?
|
| Middle Aged | 29 | 2025 | 7496 | 0.790 |
Why?
|
| Prealbumin | 1 | 2022 | 4 | 0.760 |
Why?
|
| Aged | 21 | 2025 | 5648 | 0.680 |
Why?
|
| Immunotherapy | 2 | 2025 | 171 | 0.680 |
Why?
|
| Adult | 26 | 2025 | 8131 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 153 | 0.620 |
Why?
|
| Humans | 41 | 2025 | 29214 | 0.600 |
Why?
|
| Salpingectomy | 3 | 2018 | 8 | 0.580 |
Why?
|
| Ovariectomy | 3 | 2018 | 53 | 0.570 |
Why?
|
| Patient Navigation | 1 | 2018 | 8 | 0.550 |
Why?
|
| United States Indian Health Service | 1 | 2018 | 18 | 0.540 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 19 | 0.490 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2662 | 0.480 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 2070 | 0.470 |
Why?
|
| Topotecan | 1 | 2015 | 12 | 0.470 |
Why?
|
| Status Epilepticus | 1 | 2015 | 5 | 0.460 |
Why?
|
| Leiomyoma | 2 | 2014 | 9 | 0.430 |
Why?
|
| Quality of Life | 4 | 2025 | 523 | 0.430 |
Why?
|
| Lymph Nodes | 1 | 2014 | 103 | 0.390 |
Why?
|
| Attitude to Health | 1 | 2014 | 91 | 0.390 |
Why?
|
| Indians, North American | 1 | 2018 | 548 | 0.390 |
Why?
|
| Carcinoma | 1 | 2014 | 74 | 0.390 |
Why?
|
| Perception | 1 | 2013 | 92 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 105 | 0.380 |
Why?
|
| Anxiety | 1 | 2013 | 167 | 0.360 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 26 | 0.340 |
Why?
|
| Lymph Node Excision | 6 | 2025 | 101 | 0.330 |
Why?
|
| Brachytherapy | 3 | 2025 | 54 | 0.330 |
Why?
|
| Uterine Artery Embolization | 1 | 2010 | 2 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 317 | 0.320 |
Why?
|
| Pelvis | 3 | 2025 | 38 | 0.310 |
Why?
|
| Paclitaxel | 3 | 2025 | 201 | 0.300 |
Why?
|
| Fertility Preservation | 2 | 2025 | 8 | 0.280 |
Why?
|
| Feasibility Studies | 3 | 2025 | 233 | 0.280 |
Why?
|
| Survival Analysis | 2 | 2019 | 288 | 0.270 |
Why?
|
| Young Adult | 5 | 2019 | 2877 | 0.260 |
Why?
|
| Pyridines | 2 | 2025 | 108 | 0.250 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2025 | 6 | 0.230 |
Why?
|
| Neoplasms | 2 | 2025 | 888 | 0.230 |
Why?
|
| Telomere-Binding Proteins | 1 | 2025 | 6 | 0.230 |
Why?
|
| Carcinosarcoma | 1 | 2025 | 31 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 118 | 0.220 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2025 | 53 | 0.220 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 31 | 0.220 |
Why?
|
| Vaginal Neoplasms | 1 | 2025 | 12 | 0.220 |
Why?
|
| Quality Assurance, Health Care | 1 | 2025 | 64 | 0.220 |
Why?
|
| Peritoneal Neoplasms | 1 | 2025 | 80 | 0.220 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 18 | 0.210 |
Why?
|
| Indazoles | 1 | 2024 | 18 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 80 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2022 | 643 | 0.210 |
Why?
|
| Piperidines | 1 | 2024 | 48 | 0.210 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 38 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2022 | 467 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2022 | 45 | 0.190 |
Why?
|
| BRCA2 Protein | 2 | 2024 | 21 | 0.190 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 33 | 0.190 |
Why?
|
| Vitamin D | 1 | 2022 | 54 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 1021 | 0.180 |
Why?
|
| Nomograms | 1 | 2021 | 9 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2022 | 198 | 0.170 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2021 | 22 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 29 | 0.170 |
Why?
|
| Endometrium | 2 | 2022 | 39 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2025 | 1288 | 0.150 |
Why?
|
| Granulosa Cell Tumor | 1 | 2019 | 5 | 0.150 |
Why?
|
| Ovarian Cysts | 1 | 2019 | 6 | 0.150 |
Why?
|
| Conization | 3 | 2025 | 11 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2019 | 41 | 0.150 |
Why?
|
| Biomarkers | 1 | 2022 | 790 | 0.150 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 51 | 0.140 |
Why?
|
| Adenoma | 1 | 2019 | 61 | 0.140 |
Why?
|
| Neoplasm Grading | 3 | 2025 | 108 | 0.140 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 301 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2018 | 77 | 0.130 |
Why?
|
| Antibodies, Neutralizing | 2 | 2015 | 79 | 0.130 |
Why?
|
| Adolescent | 4 | 2018 | 3255 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 15 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 303 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 303 | 0.120 |
Why?
|
| Disease-Free Survival | 3 | 2025 | 236 | 0.120 |
Why?
|
| Risk Factors | 3 | 2021 | 2144 | 0.120 |
Why?
|
| HIV Antibodies | 1 | 2015 | 3 | 0.120 |
Why?
|
| Seizures | 1 | 2015 | 50 | 0.110 |
Why?
|
| HIV-1 | 1 | 2015 | 59 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 191 | 0.110 |
Why?
|
| Uterine Hemorrhage | 1 | 2014 | 9 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 817 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 415 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 10 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 12 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 42 | 0.100 |
Why?
|
| Premenopause | 1 | 2014 | 20 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 69 | 0.100 |
Why?
|
| Gynecology | 1 | 2014 | 60 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 336 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 126 | 0.100 |
Why?
|
| HIV Infections | 1 | 2015 | 166 | 0.100 |
Why?
|
| Palliative Care | 1 | 2014 | 87 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2443 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2014 | 99 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 159 | 0.090 |
Why?
|
| Mental Health | 1 | 2013 | 111 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 139 | 0.090 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 1 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2012 | 5 | 0.090 |
Why?
|
| United States | 1 | 2018 | 2270 | 0.090 |
Why?
|
| Risk | 1 | 2012 | 138 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2025 | 165 | 0.090 |
Why?
|
| Vulvar Neoplasms | 1 | 2011 | 25 | 0.080 |
Why?
|
| Ebola Vaccines | 1 | 2010 | 1 | 0.080 |
Why?
|
| Viral Envelope Proteins | 1 | 2010 | 6 | 0.080 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2010 | 8 | 0.080 |
Why?
|
| Adenoviruses, Human | 1 | 2010 | 23 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2010 | 119 | 0.080 |
Why?
|
| Survival Rate | 2 | 2024 | 433 | 0.080 |
Why?
|
| Time Factors | 1 | 2014 | 1619 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2010 | 172 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 155 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 177 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 681 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 468 | 0.070 |
Why?
|
| Pregnancy | 2 | 2025 | 1261 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2024 | 426 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2010 | 632 | 0.070 |
Why?
|
| Age Factors | 2 | 2024 | 740 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 1033 | 0.070 |
Why?
|
| Male | 5 | 2025 | 14127 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2025 | 9 | 0.060 |
Why?
|
| Purines | 1 | 2025 | 17 | 0.060 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2025 | 13 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 35 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2025 | 63 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2025 | 109 | 0.060 |
Why?
|
| Thiosemicarbazones | 1 | 2025 | 5 | 0.060 |
Why?
|
| Carboplatin | 1 | 2025 | 121 | 0.060 |
Why?
|
| Lymphedema | 1 | 2025 | 15 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2025 | 80 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2025 | 70 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 40 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 38 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 69 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 89 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 42 | 0.050 |
Why?
|
| Homologous Recombination | 1 | 2024 | 10 | 0.050 |
Why?
|
| Phthalazines | 1 | 2024 | 25 | 0.050 |
Why?
|
| Marijuana Use | 1 | 2024 | 45 | 0.050 |
Why?
|
| Cannabis | 1 | 2024 | 48 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 69 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2025 | 903 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 16 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 51 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2022 | 65 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2022 | 106 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 136 | 0.040 |
Why?
|
| Indoles | 1 | 2022 | 112 | 0.040 |
Why?
|
| Estradiol | 1 | 2022 | 176 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 40 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 226 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 33 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 63 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 91 | 0.040 |
Why?
|
| Luteinization | 1 | 2019 | 7 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 11 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.040 |
Why?
|
| Ovary | 1 | 2019 | 73 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 93 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 119 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 686 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 382 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 46 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2016 | 28 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 24 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 34 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 213 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 466 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 172 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 8 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 52 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 140 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 614 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 417 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 99 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 24 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2010 | 8 | 0.020 |
Why?
|
| Ebolavirus | 1 | 2010 | 8 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 48 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 81 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 149 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 526 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 285 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 457 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 10806 | 0.010 |
Why?
|